Alger Mid Cap Focus Fund Class I (AFOIX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alger Mid Cap Focus Fund Class I (AFOIX) trades at $22.94 with AI Score 44/100 (Grade C). Alger Mid Cap Focus Fund Class I is a non-diversified fund that invests primarily in mid-cap companies… Market cap: $370M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for AFOIX: AFOIX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AFOIX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
AFOIX: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Alger Mid Cap Focus Fund Class I (AFOIX) Financial Services Profile
Alger Mid Cap Focus Fund Class I (AFOIX) is a non-diversified fund focusing on mid-cap equity securities, particularly within the Health Care and Software sectors. With at least 25% of its assets in these industries, AFOIX seeks long-term capital appreciation through strategic investments in specific growth areas.
What Is the Investment Thesis for AFOIX?
Alger Mid Cap Focus Fund Class I presents an investment opportunity for those seeking exposure to mid-cap companies with a focus on the healthcare and software sectors. The fund's strategy of concentrating investments in these high-growth areas could lead to significant capital appreciation. However, the non-diversified nature of the fund increases its volatility and risk profile. A key value driver is the potential for outperformance in the selected sectors, driven by innovation and increasing demand for healthcare and technology solutions. The fund's beta of 1.46 suggests higher volatility compared to the broader market. Investors may want to evaluate their risk tolerance and investment horizon when evaluating AFOIX.
Based on FMP financials and quantitative analysis
AFOIX Key Highlights
The fund invests at least 80% of its net assets in equity securities of mid-cap companies.
- At least 25% of the fund's total assets are invested in Health Care Equipment & Supplies, Health Care Technology, Biotechnology, Life Sciences Tools & Services, and/or Software industries.
- The fund is non-diversified, allowing for concentrated investments in specific companies and sectors.
- The fund has a beta of 1.46, indicating higher volatility compared to the market.
- The fund does not offer a dividend, focusing instead on capital appreciation.
Who Are AFOIX's Competitors?
AFOIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARTLX Artisan Value Fund Inv Shs | $16.02 | +0.00% | $284M | 44 |
| FNORX Fidelity Investment Trust - Fidelity Nordic Fund | $72.73 | +0.10% | $358M | — |
| PFPFX Poplar Forest Partners Fund Class A | $67.10 | -0.81% | $383M | — |
| PRCPX T. Rowe Price Credit Opportunities Fund, Inc. | $7.93 | -0.25% | $401M | — |
| PRJPX T. Rowe Price Japan | $16.05 | -0.12% | $327M | 46 |
| SOR Source Capital, Inc. | $46.29 | -0.92% | $381M | 71 |
| CAF Morgan Stanley China A Share Fund, Inc. | $19.33 | -1.23% | $325M | 87 |
| PLTS Platinum Analytics Cayman Ltd. | $17.50 | +0.00% | $316M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AFOIX's Key Strengths?
Focus on high-growth sectors like healthcare and software.
- Potential for significant capital appreciation.
- Experienced management team.
- Non-diversified strategy allows for concentrated investments.
What Are AFOIX's Weaknesses?
Non-diversified nature increases volatility.
- Sector-specific focus limits investment opportunities.
- Reliance on specific sectors exposes the fund to sector-specific risks.
- No dividend payout may deter some investors.
What Could Drive AFOIX Stock Higher?
AFOIX catalyst: Continued innovation and growth in the healthcare technology sector, driving increased demand for related products and services.
- Advancements in biotechnology and life sciences leading to new drug discoveries and therapies, boosting the value of companies in these fields.
- Increasing adoption of cloud computing and artificial intelligence, fueling growth in the software industry and benefiting companies providing related solutions.
- Potential acquisitions of mid-cap companies by larger firms seeking to expand their product offerings or enter new markets, resulting in acquisition premiums for AFOIX's holdings.
What Are the Key Risks for AFOIX?
Economic downturn impacting healthcare and software spending, leading to reduced revenue and earnings for companies in these sectors.
- Regulatory changes affecting healthcare and technology companies, such as drug pricing regulations or data privacy laws, impacting their profitability and growth prospects.
- Market volatility impacting mid-cap stocks, leading to fluctuations in the fund's net asset value (NAV).
- Competition in the asset management industry, putting pressure on management fees and potentially impacting the fund's profitability.
What Are the Growth Opportunities for AFOIX?
- Increased Investment in Healthcare Technology: The global healthcare technology market is projected to reach $662 billion by 2028, growing at a CAGR of 13.5% from 2021. AFOIX can capitalize on this growth by increasing its investments in innovative healthcare technology companies, particularly those focused on telehealth, AI-driven diagnostics, and personalized medicine. This strategic allocation can drive significant returns as these companies expand their market share and develop groundbreaking solutions.
- Expansion in Biotechnology and Life Sciences: The biotechnology and life sciences sector is experiencing rapid growth, driven by advancements in genomics, drug discovery, and personalized medicine. The global biotechnology market is expected to reach $3.88 trillion by 2030. AFOIX can benefit by investing in companies developing novel therapies, diagnostic tools, and research platforms. This includes companies focused on gene editing, immunotherapy, and precision diagnostics, which are poised for substantial growth.
- Growing Demand for Software Solutions: The software industry continues to expand, fueled by the increasing adoption of cloud computing, artificial intelligence, and digital transformation initiatives. The global software market is projected to reach $843.98 billion in 2029, growing at a CAGR of 11.7%. AFOIX can leverage this trend by investing in software companies that provide innovative solutions for various industries, including healthcare, finance, and e-commerce. This includes companies specializing in SaaS, cybersecurity, and data analytics.
- Strategic Partnerships and Acquisitions: AFOIX can enhance its portfolio performance by identifying and investing in mid-cap companies that are likely to be targets for strategic partnerships or acquisitions. Larger companies often seek to acquire innovative mid-cap firms to expand their product offerings, enter new markets, or gain access to cutting-edge technologies. By anticipating these potential deals, AFOIX can generate significant returns from acquisition premiums and increased market visibility for its portfolio companies.
- Focus on Emerging Markets: While AFOIX primarily invests in US-based companies, it can explore opportunities to invest in mid-cap companies with significant exposure to emerging markets. These markets often offer higher growth potential due to increasing consumer demand, expanding healthcare infrastructure, and rising adoption of technology. By diversifying its geographic exposure, AFOIX can tap into new sources of growth and reduce its reliance on the US market.
What Are AFOIX's Competitive Advantages?
- Expertise in selecting mid-cap companies in specific sectors.
- Established track record in asset management.
- Focus on high-growth industries like healthcare and software.
What Does AFOIX Do?
Alger Mid Cap Focus Fund Class I is a non-diversified fund managed with the objective of long-term capital appreciation. The fund strategically invests at least 80% of its net assets, alongside any borrowings for investment purposes, in the equity securities of mid-cap companies. These are generally defined as companies falling within a specific market capitalization range that aligns with the fund's investment mandate. Furthermore, the fund emphasizes investments in specific high-growth sectors, allocating at least 25% of its total assets under normal market conditions to companies operating within Health Care Equipment & Supplies, Health Care Technology, Biotechnology, Life Sciences Tools & Services, and Software. This concentration allows for a focused approach within industries demonstrating significant growth potential. The fund's non-diversified status means it can invest a significant portion of its assets in a smaller number of companies, potentially leading to higher volatility but also greater potential returns. Alger Mid Cap Focus Fund Class I operates primarily within the United States, targeting companies listed on major exchanges.
What Products and Services Does AFOIX Offer?
- Invests in equity securities of mid-cap companies.
- Focuses on companies in Health Care Equipment & Supplies.
- Targets companies in Health Care Technology.
- Allocates funds to companies in Biotechnology.
- Invests in companies in Life Sciences Tools & Services.
- Includes Software companies in its portfolio.
How Does AFOIX Make Money?
- Generates revenue through management fees based on assets under management (AUM).
- Aims to achieve capital appreciation through strategic investments.
- Focuses on specific sectors to maximize potential returns.
What Industry Does AFOIX Operate In?
Alger Mid Cap Focus Fund Class I operates within the asset management industry, focusing on mid-cap companies in high-growth sectors like healthcare and software. The asset management industry is characterized by intense competition, with firms vying for investor capital. Market trends include the increasing demand for specialized investment strategies and the growing importance of technology in asset management. Competitors include firms offering similar mid-cap focused funds, such as ARTLX, FNORX, PFPFX, PRCPX, and PRJPX. The fund's focus on specific sectors differentiates it from broader market index funds.
Who Are AFOIX's Key Customers?
- Individual investors seeking mid-cap exposure.
- Institutional investors looking for sector-specific investments.
- Retirement funds aiming for long-term growth.
Key Financial Metrics
Return on equity for Alger Mid Cap Focus Fund Class I stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. AFOIX trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
How Alger Mid Cap Focus Fund Class I Is Valued
Alger Mid Cap Focus Fund Class I carries a market capitalization of $370M, placing it in the small-cap category. Relative to its peer group, AFOIX's quantitative score of 44/100 is roughly in line with the peer average of 45/100.
AFOIX Financials
Bull Case vs Bear Case
Bull Case
- Focus on high-growth sectors like healthcare and software.
- Potential for significant capital appreciation.
- Experienced management team.
- Non-diversified strategy allows for concentrated investments.
Bear Case
- Non-diversified nature increases volatility.
- Sector-specific focus limits investment opportunities.
- Reliance on specific sectors exposes the fund to sector-specific risks.
- No dividend payout may deter some investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
AFOIX Latest News
No recent news available for AFOIX.
AFOIX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AFOIX.
Price Targets
Wall Street price target analysis for AFOIX.
AFOIX MoonshotScore
What does this score mean?
The MoonshotScore rates AFOIX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
What Investors Ask About Alger Mid Cap Focus Fund Class I (AFOIX) — Financial Services
What does the AI Score mean for AFOIX?
AFOIX holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Alger Mid Cap Focus Fund Class I is a non-diversified fund that invests primarily in mid-cap companies, with a focus on the healthcare and software industries. The fund aims to achieve long-term …
What does Alger Mid Cap Focus Fund Class I do?
Alger Mid Cap Focus Fund Class I is an actively managed, non-diversified investment fund that concentrates its investments in mid-sized companies, with a particular emphasis on the healthcare and software sectors. The fund aims to achieve long-term capital appreciation by strategically selecting companies within these high-growth industries.
What are the main risks for AFOIX?
The primary risks for Alger Mid Cap Focus Fund Class I stem from its non-diversified nature and sector concentration. Investing heavily in healthcare and software exposes the fund to sector-specific downturns and regulatory changes. Economic factors impacting these sectors, such as changes in healthcare spending or shifts in technology demand, can significantly affect the fund's performance.
What are the key factors to evaluate for AFOIX?
Alger Mid Cap Focus Fund Class I (AFOIX) holds an AI score of 44/100 (low). Alger Mid Cap Focus Fund Class I presents an investment opportunity for those seeking exposure to mid-cap companies with a focus on the healthcare and software sectors. Not financial advice.
How frequently does AFOIX data refresh on this page?
AFOIX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven AFOIX's recent stock price performance?
Alger Mid Cap Focus Fund Class I (AFOIX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-growth sectors like healthcare and software. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AFOIX overvalued or undervalued right now?
Alger Mid Cap Focus Fund Class I (AFOIX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research AFOIX before investing?
Before investing in Alger Mid Cap Focus Fund Class I (AFOIX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding AFOIX to a portfolio?
Key strength of Alger Mid Cap Focus Fund Class I (AFOIX): Focus on high-growth sectors like healthcare and software. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and is intended for informational purposes only.
- Investment decisions should be made after consulting with a qualified financial advisor.